Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationThis regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.
Updates on the ACT EU initiative, CTIS and the clinical trials landscape in the EU
The newsletter for patients, consumers and healthcare professionals
Manufacturers can request advice on their medical device clinical development programme
Guidance for Institutions and IRBs OHRP's and FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance describes OHRP's and FDA's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.
This guidance clarifies the expectations on the application of the EU guidance on good pharmacovigilance practices (GVP) - guidance notes updated.
Link to Expression of Interest form added 10th Feb. 2025
Confirmation of when it is expected to come into force.
Released 3rd Feb 2025
Our current strategy was written to last three years, and now we’re planning a new strategy, starting in 2025, which will set out what we are going to do to deliver our mission over the next three years.